Enzon Pharmaceuticals 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Rick Feinstein

최고 경영자

US$209.5k

총 보상

CEO 급여 비율	n/a
CEO 임기	10.2yrs
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	3.5yrs

최근 관리 업데이트

Recent updates

CEO

Rick Feinstein (80 yo)

10.2yrs

테뉴어

US$209,452

보상

Mr. Richard L. Feinstein, also known as Rick, CPA, has been Chief Executive Officer and Company Secretary at Enzon Pharmaceuticals Inc. since February 26, 2021. He had been Vice President of Finance at Enz...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Randolph Read	Independent Chairman	3.5yrs	US$36.67k	0.27% € 16.8k
Jaffery Firestone	Independent Director	1.7yrs	US$11.38k	데이터 없음
Jordan Bleznick	Independent Director	3.5yrs	US$36.67k	0.13% € 8.4k

3.5yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: EZ1 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.

Enzon Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Enzon Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Enzon Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2022

Enzon Pharmaceuticals, Inc. Appoints Richard L. Feinstein as Secretary

Recent updates

Enzon Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2024

Full year 2022 earnings released: US$0.02 loss per share (vs US$0.034 loss in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.007 loss per share (vs US$0.01 loss in 3Q 2021)

First half 2022 earnings released

High number of new and inexperienced directors

High number of new and inexperienced directors

First quarter 2022 earnings released: US$0.011 loss per share (vs US$0.007 loss in 1Q 2021)

Enzon Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2021 earnings released: US$0.01 loss per share (vs US$0.009 loss in 3Q 2020)

First quarter 2021 earnings released: US$0.007 loss per share (vs US$0.005 loss in 1Q 2020)

CEO & Secretary Andrew Rackear has left the company

Full year 2020 earnings released: US$0.035 loss per share (vs US$0.022 loss in FY 2019)

New 90-day high: €0.36

New 90-day high: €0.30

Enzon Pharmaceuticals, Inc. Appoints Richard L. Feinstein as Secretary

Third quarter 2020 earnings released: US$0.009 loss per share

New 90-day high - €0.21

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령